Literature DB >> 10088044

Benefits and pitfalls encountered in psychiatric genetic association studies.

A K Malhotra1, D Goldman.   

Abstract

The genetic association strategy is currently being applied to a number of psychiatric phenotypes including disease vulnerability, personality variation and clinical response to psychotropic drugs. Association studies offer the prospect of identification of the specific alleles that confer significant effects on clinical phenotype. However, it should be noted that this strategy has additional advantages as well as unique drawbacks. In this paper, we review the basic methodology utilized in each step of a typical psychiatric genetic association study and discuss their potential benefits and pitfalls with particular emphasis on the selection of clinical phenotype, the identification of a candidate gene, the selection of a candidate variant, clinical data set design, and the statistical analysis of association data. With appropriate design and execution, it is hoped that the association strategy will prove to be as successful in psychiatry as it has proven to be in other branches of medicine.

Entities:  

Mesh:

Year:  1999        PMID: 10088044     DOI: 10.1016/s0006-3223(98)00365-5

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  19 in total

1.  Candidate gene studies in psychiatric disorders: promises and limitations.

Authors:  L Sher
Journal:  J Psychiatry Neurosci       Date:  2001-03       Impact factor: 6.186

Review 2.  Genetic studies of autism: from the 1970s into the millennium.

Authors:  M Rutter
Journal:  J Abnorm Child Psychol       Date:  2000-02

Review 3.  Pharmacogenetics of antipsychotic-induced weight gain.

Authors:  Christoph U Correll; Anil K Malhotra
Journal:  Psychopharmacology (Berl)       Date:  2004-07-08       Impact factor: 4.530

Review 4.  Genetics and psychopharmacology: prospects for individualized treatment.

Authors:  Charles U Nnadi; Joseph F Goldberg; Anil K Malhotra
Journal:  Essent Psychopharmacol       Date:  2005

5.  The future of pharmacotherapy for schizophrenia.

Authors:  John M Kane; Anil Malhotra
Journal:  World Psychiatry       Date:  2003-06       Impact factor: 49.548

Review 6.  [Neurogenetics of emotional processes. Neuroimaging findings as endophenotypes for depression].

Authors:  U Dannlowski; C Konrad; V Arolt; T Suslow
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

Review 7.  Identification of neurogenetic pathways of risk for psychopathology.

Authors:  Patrick M Fisher; Karen E Muñoz; Ahmad R Hariri
Journal:  Am J Med Genet C Semin Med Genet       Date:  2008-05-15       Impact factor: 3.908

8.  A pilot genome wide association and gene expression array study of suicide with and without major depression.

Authors:  Hanga Galfalvy; Gil Zalsman; Yung-Yu Huang; Lauren Murphy; Gorazd Rosoklija; Andrew J Dwork; Fatima Haghighi; Victoria Arango; J John Mann
Journal:  World J Biol Psychiatry       Date:  2011-11-07       Impact factor: 4.132

9.  AKAP10 (I646V) functional polymorphism predicts heart rate and heart rate variability in apparently healthy, middle-aged European-Americans.

Authors:  Serina A Neumann; Whittemore G Tingley; Bruce R Conklin; Catherine J Shrader; Eloise Peet; Matthew F Muldoon; J Richard Jennings; Robert E Ferrell; Stephen B Manuck
Journal:  Psychophysiology       Date:  2009-05       Impact factor: 4.016

10.  DISC1 is associated with prefrontal cortical gray matter and positive symptoms in schizophrenia.

Authors:  Philip R Szeszko; Colin A Hodgkinson; Delbert G Robinson; Pamela Derosse; Robert M Bilder; Todd Lencz; Katherine E Burdick; Barbara Napolitano; Julia D Betensky; John M Kane; David Goldman; Anil K Malhotra
Journal:  Biol Psychol       Date:  2007-11-01       Impact factor: 3.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.